tbuckley/cabot-search huggingface dataset:
OP0135 Erectile Dysfunction is Common among Gout Patients
Authors: N. Schlesinger, D.C. Radvanski, J. Fischkoff, J.B. Kostis
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Erectile dysfunction (ED) is common in the general population. The likelihood of ED increases progressively with age; however, it is not an inevitable consequence of aging. The importance of vascular disease as an underlying cause of ED is well established. Patients who present with ED have an increased rate of cardiovascular disease (CVD) risk factors and concomitant silent coronary artery disease (CAD). Gout and hyperuricemia are commonly associated with CVD risk factors and CAD. <h3>Objectives</h3> To determine whether men with gout may have an increased prevalence of ED as compared to men without gout. <h3>Methods</h3> In this cross sectional study, men aged 18-89 presenting to the Rheumatology clinic between 8/26/10 and 5/13/2013, were asked to participate. The presence of ED was determined by filling out a Sexual Health Inventory in Men (SHIM). The SHIM classifies ED into one of five categories: absent (26–30), mild (22–25), mild to moderate (17–21), moderate (11–16) and severe (1–10). The patient9s history, physical examination and recent laboratory studies were reviewed as well. Descriptive statistics and subgroup analyses were used to summarize the data. We used chi-square tests for independence to compare categorical variables. <h3>Results</h3> Of the 201 men surveyed 83 had gout. A significantly greater proportion of gout patients had ED (n=63;76%) compared with patients without gout (n=61;52%) (p=0.0007). A significantly greater proportion of gout patients (43%) had severe ED compared with patients without gout (30%) (p=0.007). The mean SHIM score of all patients was 16.88 (SD ±-0.83). Gout patients had an average SHIM score of 14.38 (SD ±1.01) versus 18.53 (SD ±0.964) in patients without gout (p&lt;0.0001). A significantly greater proportion of gout patients whose age was ≥65 had ED versus patients without gout (p=0.0001) and it was significantly more likely to be severe ED versus patients without gout (p=0.0002). A significantly greater proportion of patients with tophaceous gout had ED versus those without tophi (p=0.0001). In a multivariate analysis the association between gout and ED remained statistically significant even after adjusting for age (p=0.0009), hypertension, LDL, GFR, obesity, depression (p=0.0154) and diabetes (p=0.0085). <h3>Conclusions</h3> ED is present in most men with gout and is frequently severe. Increasing awareness of the presence of ED in gout patients may lead to earlier medical attention and treatment as well as evaluation of possible silent CAD. We propose that all men with gout be routinely screened for ED. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1156
A 38-Year History of Natural-Killer-Cell Lymphoma
Authors: Carsten Schrader, Dirk Janssen, Michael Kneba, Karl Lennert
Journal: New England Journal of Medicine (2004)

To the Editor: In February 1965, a 19-year-old man presented with an extranodal natural-killer-cell–T-cell lymphoma, nasal type, affecting the nasal cavity. One of us made the diagnosis of “granuloma gangraenescens,” which was considered to be an unclassifiable sarcoma of the reticulohistiocytic system.1 The biopsy specimens (Figure 1) were also reviewed in 1965 by Friedrich Wegener, who confirmed the diagnosis and ruled out Wegener's granulomatosis. Surgical resection and radiotherapy induced a complete remission, which lasted for 33 years. In 1998, the now 52-year-old patient had a relapse with skin lesions, which responded to radiochemotherapy. In 2002, the disease progressed, with nasal . . .
F-18 FDG Avid Primary CNS Lymphoma Located in the Ventricles
Authors: Nalan Can, Hakan Ulubay, Hakan Yakupoğlu, Bülent Celasun, Mustafa Unlü
Journal: Clinical Nuclear Medicine (2011)

Primary malignant lymphoma is a non-Hodgkin lymphoma which occurs in the brain in the absence of systemic involvement. A 63-year-old woman presented to emergency service, complaining of sudden onset vomiting and dizziness. She was unconscious when she was admitted to the hospital. She had no complain, until a week ago when she experienced a headache nonresponding to analgesic. Preliminary diagnosis was cerebrovascular hemorrhage or intracranial mass. Magnetic resonance imaging and PET/CT yielded a mass filling all ventricles. Histopathology of the mass matched with malignant lymphoma located in the ventricles.
Effect of Ticlopidine on the Long-Term Patency of Saphenous-Vein Bypass Grafts in the Legs
Authors: Jean-Pierre Becquemin
Journal: New England Journal of Medicine (1997)

Optimal therapy to prevent late occlusion of arterial bypass grafts in the legs has not been determined. We assessed the effect of ticlopidine, an inhibitor of platelet aggregation, on the long-term patency of saphenous-vein bypass grafts for the treatment of peripheral vascular disease.
ANTITHROMBOTIC MEDICATION AND OUTCOMES AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH ATRIAL FIBRILLATION NOT UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
Authors: Gorav Batra, Leif Friberg, David Erlinge, Stefan James, Tomas Jernberg, Bodil Svennblad, Lars Wallentin, Jonas Oldgren
Journal: Journal of the American College of Cardiology (2015)
Abstract 2330: Role of RET finger protein in the integrin beta1 expression in cancer cells and its significance in cancer patients
Authors: Takuya Kato, Atsushi Enomoto, Naoya Asai, Yoshiki Murakumo, Masahide Takahashi
Journal: Cancer Research (2011)

Abstract Integrins play central roles in the biology by regulating cell adhesion to the extracellular matrix and cell migration, growth, differentiation and apoptosis. Although contribution of integrins on cancer development has been well studied, the mechanism of the regulation of integrins expression remains elusive. Here we report that RET finger protein (RFP) regulates integrin beta1 expression in cancer cells. RNAi-mediated depletion of RFP resulted in decrease of integrin beta1 expression and impaired cell migration/invasion. RNA immunoprecipitation assay revealed that RFP interacts with integrin beta1 mRNA, and RFP knockdown caused destabilization of the mRNA. Furthermore, we examined the expression of RFP in human colon cancer and endometrial cancer, and assessed its clinical significance. High levels of RFP expression correlated with poor clinical outcome in colon cancer and endometrial cancer patients. These findings suggest that RFP regulates the cancer cell migration/invasion through the upregulation of integrin beta1 expression by stabilization of its mRNA, and expression of RFP can be a prognostic marker for an unfavorable clinical outcome in patients with colon cancer and endometrial cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2330. doi:10.1158/1538-7445.AM2011-2330
ES8-3: Measuring Outcomes in Breast Reconstruction: The Patient Perspective.
Authors: A Pusic
Journal: Cancer Research (2011)

Abstract In breast reconstruction, understanding patients’ perceptions of surgical results is of primary importance. As new reconstructive techniques continue to advance, surgeons and patients require high quality information on key outcomes such as patient satisfaction and quality of life. The need for meaningful data is further accentuated by concerns over healthcare expenditures and the increasing involvement of patients in their own surgical decision-making. Patient-reported outcome (PRO) measures are questionnaires specifically designed to quantify aspects of outcome such as patient satisfaction and health-related quality of life. When developed and validated according to internationally recognized standards, PRO measures can provide reliable and valid assessment of patient outcomes. Traditionally, PRO measures were used in clinical research alone; however, advances in psychometric methods have now facilitated the development of a new generation of PRO measures that are also useful in clinical care. This presentation will provide an overview of PRO research in breast reconstruction. The BREAST-Q, a new PRO measure for breast surgery patients, will be highlighted. Physicians will gain the necessary critical appraisal skills to interpret and apply evidence from PRO studies in their own clinical practice. Approaches to routine use of PRO measures in clinical care will also be described. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr ES8-3.
Validation of FOXA1 as a Prognostic Marker in Breast Cancer in a Large Population-Based Tissue Microarray.
Authors: S. Badve, R. Mehta, R. Jain, T. Nielsen, S. Leung, D. Huntsman, H. Nakshatri
Journal: Cancer Research (2009)

Abstract FOXA (Forkhead box protein A) proteins play major roles in development and differentiation. However, recently, FOXA1 has been identified to play a role in controlling nearly 50% of estrogen receptor target genes and has been deemed as a 'pioneer factor'. It is believed to have a dual role in breast cancer: (1) growth promotion by coactivating ERα and (2) growth inhibition by regulating factors like p27Kip1 and E-cadherin. We studied the expression of FOXA1 in a population based tissue microarray of 4,046 invasive breast cancer cases with a median follow- up of 12.4 years using immunohistochemistry and studied its correlation with estrogen receptor and other clinicopathological variables. The percent positivity (P) and intensity (I) of nuclear FOXA1 expression were multiplied to generate a numerical score (S = P × I) that ranged from 0 to 30. Scores between 0 and 3 were defined as low FOXA1 expression and 4 to 30 were defined as high FOXA1 expression. Variable FOXA1 expression was noted in the 3581 interpretable tumors: none (10.6%), weak (3.5%), moderate (19.3%) and strong (55.1%). High level of FOXA1 expression (FOXA1 score greater than 3) was seen in nearly 86% of the tumors. FOXA1 expression correlated positively with ER (p&amp;lt; 0.0001), PR (p&amp;lt; 0.0001), E-cadherin (p&amp;lt;0.0001), age (p&amp;lt; 0.0001) and negatively with basal subtype (p&amp;lt; 0.0001), Ki67 (p&amp;lt;0.0001), tumor size (p&amp;lt; 0.0001) and tumor grade (p&amp;lt;0.0001). Univariate analyses showed small tumor size (T1 tumors), low grade (Grade I), node negative disease, absence of lymphovascular invasion, ER, PR, Her2, cyclin D1 and Ki67 as independent predictors of better overall survival. Patients with Luminal A subtype breast cancers had better overall survival than those with non-Luminal A subtype breast cancers. FOXA1 is found to be a significant predictor of breast cancer specific survival (p=0.012) and locoregional relapse free survival (p=0.0001). However, FOXA1 did not reach statistical significance for disease free survival (p=0.110) and distant relapse free survival (p=0.147). When stratified by molecular subtypes using IHC, FOXA1 did not show any trend for overall survival. In those treated with tamoxifen, low FOXA1 expression was associated with poor overall survival (p&amp;lt;0.0001). In a subset of ERα-positive breast cancer cases, FOXA1 was a significant predictor of breast cancer specific survival (p=0.012). To summarize, FOXA1 expression in ERα-positive breast cancer is of prognostic significance. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 2130.
Abstract PD06-06: Novel Surgical Technique To Assess the Response of Metastatic Axillary Lymph Nodes to Neoadjuvant Chemotherapy in Breast Cancer Patients
Authors: M-JTFD Vrancken Peeters, M Straver, M Donker, C Loo, J Wesseling, M Holtkamp, ETJ Rutgers, S. Rodenhuis
Journal: Cancer Research (2010)

Abstract Background: An important benefit of neoadjuvant chemotherapy (NAC) is the increase in breast-conserving surgery. At present the response of axillary lymph node metastases to chemotherapy is not assessed accurately, since SN biopsy either before or after NAC will not provide an accurate answer. Therefore a reliable axilla-conserving therapy is not yet a benefit. We developed a new surgical technique to evaluate the axillary nodal response by Marking of the Axillary lymph node with Radioactive Iodine seeds (= the MARI procedure) Method: Prior to NAC, tumor positive axillary lymph nodes were marked with a Iodine-125 seed under ultrasound guidance (the MARI node). After NAC, the marked lymph node was selectively removed with the use of a gamma-detection probe. A complementary axillary lymph node dissection was performed to assess whether the pathological response in the marked node was indicative for the pathological response in the additional lymph nodes. Results: In 44 patients who were scheduled for NAC the MARI procedure was attempted. In 42 patients the tumor-positive axillary lymph node was successfully marked with a radioactive Iodine-125 seed. Two patients appeared to have overt distant metastasis and did not undergo complete axillary dissection. Thus, in 40 patients the MARI node was selectively removed after NAC. In all these patients a complementary axillary lymph node dissection was performed. In 24 patients the MARI node contained a macrometastasis after NAC. In 4 patients only isolated tumor cells (ITC) were present in the MARI node. In 24 of these 28 patients further nodal involvement was found. More importantly: in 12 patients (=30%) no residual tumor was present in the MARI node (pathological complete response= pCR) and 10 of them also showed a pCR in the complementary axillary lymph node dissection. In one patient a macrometastasis, and in one, ITC were found in one of the additional nodes. Conclusion: In this study we present the first results of a new surgical technique to assess the response of metastatic lymph nodes in the context of NAC for breast cancer; the MARI procedure. We conclude that marking tumor-positive lymph nodes before NAC and selectively removing them after NAC is feasible. Moreover we report that this MARI node is indicative for the response to NAC in the other axillary nodes: in 30% of the treated patients an axillary pCR was found which was correctly indicated by a negative MARI node in all but one patient. Thus the MARI procedure will enable us to select patients in which axillary lymph node dissection can be avoided after NAC. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr PD06-06.
Renal Axis Deviation in Urinary Tract Abnormalities of Children
Authors: Kianoush Ansari-Gilani, Ali Gholamrezanezhad, Davood Beiki, Sahar Mirpour, Jamak Modaresi Esfeh
Journal: Clinical Nuclear Medicine (2011)

Urinary tract pathologies are common in children. Previous reports suggested a relationship between some renal pathologies and renal anatomic variations. This study evaluates the effect of different urinary tract abnormalities on scintigraphic renal long axis.Children referred to our nuclear medicine department for Tc-99m dimercaptosuccinic acid and/or Tc-99m N,N-ethylenedicysteine renal scintigraphies were entered consecutively. Presence of single, ectopic, or fused kidneys, extrarenal pathologies altering renal long axis, and history of renal surgery or advanced renal disease were used as exclusion criteria. If indicated, patients were assessed for vesicoureteral reflux (VUR). Long renal axis of each kidney was drawn with a line passing through the kidney's upper and lower poles using posterior image. The angle between this axis and patient's longitudinal body axis was defined as "renal angle." After defining age-groups, "age-corrected renal angle" was calculated.A total of 311 cases (622 kidney units) entered the study (183 females, 128 males). Mean age was 41.8 months. Mean "renal angle" was 11.7, 11.9, 14.1, 17.6, 28.5, 16.7, and 19.2 degrees in normal, mild, moderate, and severe VUR, high-grade ureteropelvic junction (UPJ) obstruction, nonobstructive pelvic dilatation, and ureterovesical junction obstruction, respectively (P = 0.000). Applying receiver operating characteristic analysis and using ultrasonography as the gold standard, renal angle deviation of 13.75 degrees led to the sensitivity of 74.6% and specificity of 70.7% to detect pyelocalyceal system dilatation. Using a "renal angle" cutoff value of 18.7 degrees, 85% sensitivity and 85% specificity were achieved for the diagnosis of high-grade UPJ obstruction. Using "age-corrected renal angle," a cutoff value of 3.9 degrees was consistent with 60% sensitivity and 73% specificity for the diagnosis of severe VUR.Considerable renal axis deviation is noted in patients with UPJ obstruction and severe VUR in children. Measurement of "renal angle" provides indirect but useful clues to the presence of urinary tract pathologies. Renal scintigraphy is a useful tool for drawing renal axis and measuring "renal angle," potentially making it useful for prediction of urinary tract system abnormalities.
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Authors: Leonard B. Saltz, John V. Cox, Charles Blanke, Lee S. Rosen, Louis Fehrenbacher, Malcolm J. Moore, Jean A. Maroun, Stephen P. Ackland, Paula K. Locker, Nicoletta Pirotta, Gary L. Elfring, Langdon L. Miller
Journal: New England Journal of Medicine (2000)

The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer. Irinotecan prolongs survival in patients with colorectal cancer that is refractory to treatment with fluorouracil and leucovorin. In a multicenter trial, we compared a combination of irinotecan, fluorouracil, and leucovorin with bolus doses of fluorouracil and leucovorin as first-line therapy for metastatic colorectal cancer. A third group of patients received irinotecan alone.
Abstract 3490: Identification and characterization of novel galectin-9 splice variants in endothelial cells
Authors: Roy Heusschen, Martijn de Bree, Arjan W. Griffioen, Victor Ljl Thijssen
Journal: Cancer Research (2011)

Abstract Evidence is accumulating that endothelial galectins play an important role in tumor angiogenesis. Recently, we reported altered galectin-9 expression during endothelial cell activation. Here, we further assessed the expression and function of galectin-9 in endothelial cells. Using cDNA flanking PCR and subsequent cloning we identified 5 different galectin-9 splice variants in endothelial cells, 2 of which result in truncation of the C-terminal carbohydrate recognition domain and one of which has not been described previously i.e. galectin-9Δ5/6/10. By real-time PCR analysis we confirmed the expression of these 5 splice variants in endothelial cells and found that galectin-9Δ5 is the dominant splice variant in endothelial cells, as has been described for most other cell types. Endothelial cell activation resulted in a decreased expression of total galectin-9 levels which was mainly due to a decrease in galectin-9Δ5 expression. The expression of 2 other splice variants, galectin-9Δ5/6 and galectin-9Δ5/6/10 was retained after cell activation. To study the functional consequences of alternative splicing patterns on endothelial cell function, we cloned the 5 endothelial galectin-9 splice variants into expression constructs. We were able to demonstrate efficient transcription/translation of galectin-9 splice variants by real time PCR and Western blot respectively, following transfection of cell lines from non-endothelial (HEK293T) and endothelial (HMEC) origin. These data confirmed that exclusion of exon 10 causes a frameshift and premature stopcodon, resulting in the generation of protein that lacks the C-terminal CRD. Next, we assessed the function of gal-9 splice variants in endothelial cells by determining the effects on endothelial cell proliferation, migration and sprouting. Finally, we explored whether these splice variants have diverging roles in regulating the interaction between endothelial cells and immune cells. In conclusion, we report that endothelial cells express 5 splice variants of gal-9, one of which has not been described previously, and we show that these splice variants have diverging roles in endothelial cell biology. We hypothesize that interfering with the function of endothelial gal-9 splice variants might be an interesting approach for novel anti-cancer therapies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3490. doi:10.1158/1538-7445.AM2011-3490
Professor was harassed by his university after criticising routine prostate cancer screening, inquiry finds
Authors: J. Lenzer
Journal: BMJ (2012)

A prominent medical school professor has been subjected by his university to “egregious” harassment after he wrote an editorial critical of routine prostate cancer screening, according to an internal investigation at the university.

Michael Wilkes, former vice dean for medical education and now director of Global Health, a research and policy institute, and professor of medicine at the University of California Davis, co-wrote an editorial published in the San Francisco Chronicle on 30 September 2010, with Jerome R Hoffman, emeritus professor of medicine at the University of California Los Angeles. 

Wilkes and Hoffman, who were serving as researchers/consultants to the US Centers for Disease Control and Prevention, wrote that routine prostate cancer screening “can cause more harm than good” and said that men should be full participants in the decision to be screened through a process of “shared decision making.”

Wilkes told the BMJ that he was moved to write the editorial after some of his students told him in mid September 2010 about a free university seminar for the public on “men’s health” to be held at the end of the month. 

The seminar featured a “special guest,” three time Super Bowl Champion, Guy McGuire. An advertisement for the event stated that “Prostate Defense Begins at 40” and “Know Your Stats About …